A phase I and pharmacokinetic study of intravenous vinzolidine.

Abstract

The semi-synthetic vinca alkaloid vinzolidine was administered to advanced cancer patients as an intravenous bolus on a three day schedule every 21 days. Forty-two patients were treated in this phase I trial. Five partial remissions (breast--1, melanoma--2, renal cancer--2) were seen in 30 evaluable patients. The dose limiting toxicities were myelosuppression and neuropathy. Erratic myelosuppression from course to course within the same patient as seen in previous trials with oral vinzolidine, was not observed with the intravenous formulation. The measured pharmacokinetic parameters conformed best to a 2-compartment model with a mean terminal half-life of 23 hours. The anti-tumor activity observed during this phase I trial and acceptable toxicity provide the basis for initiating phase II studies in selected forms of cancer.

• Authors: C W Taylor, S E Salmon, W G Satterlee, A B Robertone, T M McCloskey, M T Holdsworth, P M Plezia, D S Alberts
• Journal: Investigational new drugs (Invest New Drugs) Vol. 8 Suppl 1 Pg. S51-7 ( 1990) ISSN: 0167-6997 [Print] United States
• PMID: 2380017 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Vinca Alkaloids
• vinzolidine

Topics

• Adult
• Aged
• Antineoplastic Agents (administration & dosage, pharmacokinetics, therapeutic use, toxicity)
• Drug Evaluation
• Female
• Humans
• Injections, Intravenous
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Vinca Alkaloids (administration & dosage, pharmacokinetics, therapeutic use, toxicity)